Endra Life Sciences INC. (NDRA) — SEC Filings

Overview

Endra Life Sciences INC. (NDRA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 25, 2026: ENDRA Life Sciences Inc. filed an 8-K on March 25, 2026, reporting activities related to Item 2.05 (Costs Associated with Exit or Disposal Activities) and Item 7.01 (Regulation FD Disclosure), with a period of report of March 19, 2026. This indicates the company is undergoing significant restructuri

Sentiment Summary

Across 44 filings, the sentiment breakdown is: 1 bullish, 5 bearish, 34 neutral, 4 mixed. The dominant filing sentiment for Endra Life Sciences INC. is neutral.

Filing Type Overview

Endra Life Sciences INC. (NDRA) has filed 23 8-K, 6 10-Q, 3 DEF 14A, 1 8-K/A, 4 S-1/A, 1 10-K/A, 2 10-K, 1 10-Q/A, 1 DEFA14A, 1 SC 13G, 1 S-1 with the SEC between Mar 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (44)

• 8-K Filing — 8-K · Apr 21, 2026
• ENDRA Life Sciences Reports Exit/Disposal Activities in 8-K — 8-K · Mar 25, 2026
  ENDRA Life Sciences Inc. filed an 8-K on March 25, 2026, reporting activities related to Item 2.05 (Costs Associated with Exit or Disposal Activities) and Item
• 8-K Filing — 8-K · Dec 15, 2025
• 8-K Filing — 8-K · Nov 28, 2025
• ENDRA's Losses Narrow, Cash Dwindles Amid Crypto Pivot — 10-Q · Nov 14, 2025 Risk: high
  ENDRA Life Sciences Inc. reported a net loss of $1,595,959 for the three months ended September 30, 2025, a significant improvement from the $2,354,090 net loss
• ENDRA Life Sciences Files 8-K for Material Agreement — 8-K · Oct 30, 2025 Risk: medium
  ENDRA Life Sciences Inc. filed an 8-K on October 30, 2025, reporting an event that occurred on October 29, 2025. The filing indicates an entry into a material d
• ENDRA Seeks Massive Share Authorization Hike, Officer Exculpation — DEF 14A · Oct 28, 2025 Risk: high
  ENDRA Life Sciences Inc. (NDRA) is holding its 2025 Annual Meeting on December 9, 2025, to address several critical proposals. Key among these is a proposed ame
• ENDRA Life Sciences Files 8-K — 8-K · Oct 23, 2025 Risk: low
  ENDRA Life Sciences Inc. filed an 8-K on October 23, 2025, reporting on various events. The filing includes information related to financial statements and exhi
• ENDRA Life Sciences Files 8-K/A to Correct Technical Filing Errors — 8-K/A · Oct 15, 2025 Risk: low
  ENDRA Life Sciences Inc. filed an amendment (8-K/A) on October 15, 2025, to a previous filing from October 10, 2025. This amendment corrects a technical error i
• ENDRA Narrows Q2 Loss Amidst Deep Cost Cuts, Cash Dwindles — 10-Q · Aug 14, 2025 Risk: high
  ENDRA Life Sciences Inc. reported a net loss of $1,225,912 for the three months ended June 30, 2025, a significant improvement from the $2,229,153 net loss in t
• ENDRA Files S-1/A for Continuous Offering, Signaling Capital Raise — S-1/A · Jul 25, 2025 Risk: high
  ENDRA Life Sciences Inc. (NDRA) filed an S-1/A on July 25, 2025, for a delayed or continuous offering of securities, indicating a capital raise strategy rather
• ENDRA Life Sciences Files 8-K — 8-K · Jul 23, 2025 Risk: medium
  ENDRA Life Sciences Inc. filed an 8-K on July 23, 2025, to report other events. The filing does not contain specific details about the nature of these events, d
• ENDRA Life Sciences Amends S-1, Signals Capital Raise Intent — S-1/A · Jul 16, 2025 Risk: medium
  ENDRA Life Sciences Inc. (NDRA) filed an S-1/A on July 16, 2025, for a continuous offering of securities under Rule 415, indicating a strategic move to raise ca
• ENDRA Life Sciences Files 8-K on Financials — 8-K · Jul 9, 2025 Risk: low
  ENDRA Life Sciences Inc. filed an 8-K on July 9, 2025, reporting on its results of operations and financial condition. The filing includes financial statements
• ENDRA Life Sciences Files 8-K for Regulation FD Disclosure — 8-K · Jun 11, 2025 Risk: low
  ENDRA Life Sciences Inc. filed an 8-K on June 11, 2025, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or material
• ENDRA Life Sciences Faces Delisting Concerns — 8-K · May 30, 2025 Risk: high
  ENDRA Life Sciences Inc. filed an 8-K on May 30, 2025, reporting a notice of delisting or failure to meet continued listing standards. The company's principal e
• ENDRA Life Sciences Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: medium
  ENDRA Life Sciences Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $25,251,790 and total liabilities of $3,000,0
• ENDRA Life Sciences Corrects 10-K Auditor Report Details — 10-K/A · Apr 7, 2025 Risk: low
  ENDRA Life Sciences Inc. filed an amendment (Amendment No. 1) to its 2024 Form 10-K on April 7, 2025, to correct a typographical error in the auditor's report f
• ENDRA Life Sciences Files 2024 10-K — 10-K · Mar 31, 2025 Risk: medium
  ENDRA Life Sciences Inc. filed its 2024 10-K on March 31, 2025, reporting on its fiscal year ending December 31, 2024. The company, focused on electromedical ap
• ENDRA Life Sciences Files 8-K — 8-K · Nov 22, 2024 Risk: low
  ENDRA Life Sciences Inc. filed an 8-K on November 22, 2024, reporting on other events and financial statements. The filing details the company's principal execu
• ENDRA Life Sciences Files 10-Q/A Amendment — 10-Q/A · Nov 21, 2024 Risk: medium
  ENDRA Life Sciences Inc. filed an amended 10-Q for the period ending September 30, 2024. The filing details financial information and subsequent events, includi
• ENDRA Life Sciences Files Q3 2024 10-Q — 10-Q · Nov 19, 2024 Risk: medium
  ENDRA Life Sciences Inc. filed its 10-Q for the quarterly period ended September 30, 2024. The company, incorporated in Delaware, is based in Ann Arbor, MI, and
• ENDRA Life Sciences Files 8-K on Financials — 8-K · Nov 15, 2024 Risk: low
  ENDRA Life Sciences Inc. filed an 8-K on November 15, 2024, reporting on its results of operations and financial condition. The filing includes financial statem
• ENDRA Life Sciences Files 8-K on Security Holder Rights — 8-K · Nov 5, 2024 Risk: medium
  ENDRA Life Sciences Inc. filed an 8-K on November 4, 2024, reporting material modifications to the rights of security holders and amendments to its articles of
• ENDRA Life Sciences Files 8-K on Corporate Matters — 8-K · Oct 29, 2024 Risk: low
  ENDRA Life Sciences Inc. filed an 8-K on October 29, 2024, reporting on matters submitted to a vote of security holders and other events that occurred on Octobe
• ENDRA Life Sciences Files Additional Proxy Materials — DEFA14A · Sep 17, 2024 Risk: low
  ENDRA Life Sciences Inc. filed a Definitive Additional Materials (DEFA14A) on September 17, 2024, related to its proxy statement. The filing concerns the compan
• ENDRA Life Sciences Files Definitive Proxy Statement — DEF 14A · Sep 16, 2024 Risk: low
  ENDRA Life Sciences Inc. filed a definitive proxy statement (DEF 14A) on September 16, 2024, for its annual meeting. The filing details the company's governance
• ENDRA Life Sciences Files 8-K — 8-K · Aug 28, 2024 Risk: low
  ENDRA Life Sciences Inc. filed an 8-K on August 28, 2024, reporting on various events. The filing includes information related to Regulation FD disclosures, oth
• ENDRA Life Sciences Files 8-K on Financials — 8-K · Aug 23, 2024 Risk: low
  ENDRA Life Sciences Inc. filed an 8-K on August 23, 2024, reporting on its results of operations and financial condition as of August 22, 2024. The filing inclu
• ENDRA Life Sciences Files 8-K with Corporate Updates — 8-K · Aug 16, 2024 Risk: medium
  ENDRA Life Sciences Inc. filed an 8-K on August 16, 2024, reporting material modifications to the rights of security holders and amendments to its articles of i
• ENDRA Life Sciences Q2 2024 10-Q Filed — 10-Q · Aug 14, 2024 Risk: medium
  ENDRA Life Sciences Inc. filed its Q2 2024 10-Q report on August 14, 2024, detailing financial performance for the period ending June 30, 2024. The company repo
• ENDRA Life Sciences Appoints New CEO, Directors, and Incentive Plan — 8-K · Aug 13, 2024 Risk: medium
  ENDRA Life Sciences Inc. announced on August 12, 2024, a series of significant corporate actions. These include the election of two new directors, Dr. Jonathan
• Samsung Medical to Acquire ENDRA Life Sciences for $50M — 8-K · Aug 9, 2024 Risk: medium
  ENDRA Life Sciences Inc. announced on August 5, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of Samsung Medical for appr
• ENDRA Life Sciences Faces Delisting Notice — 8-K · Jul 17, 2024 Risk: high
  ENDRA Life Sciences Inc. filed an 8-K on July 17, 2024, reporting a notice of delisting or failure to meet continued listing standards as of July 15, 2024. The
• ENDRA Life Sciences Files Proxy Statement for August Meeting — DEF 14A · Jun 25, 2024 Risk: low
  ENDRA Life Sciences Inc. filed its definitive proxy statement (DEF 14A) on June 25, 2024, for its annual meeting on August 6, 2024. The filing concerns the soli
• SC 13G Filing — SC 13G · Jun 14, 2024
• ENDRA Life Sciences Files 8-K: Material Agreement — 8-K · Jun 6, 2024 Risk: medium
  ENDRA Life Sciences Inc. announced on June 4, 2024, that it entered into a material definitive agreement. The company also disclosed information related to Regu
• ENDRA Life Sciences Files S-1/A Amendment — S-1/A · May 31, 2024 Risk: medium
  ENDRA Life Sciences Inc. filed an S-1/A amendment on May 31, 2024, related to its registration statement (No. 333-278842). The company, incorporated in Delaware
• ENDRA Life Sciences Files 8-K — 8-K · May 20, 2024 Risk: low
  ENDRA Life Sciences Inc. filed an 8-K on May 20, 2024, reporting on other events and financial statements. The filing does not contain specific dollar amounts o
• ENDRA Life Sciences Inc. Files 10-Q for Q1 2024 — 10-Q · May 14, 2024 Risk: medium
  ENDRA Life Sciences Inc. (NDRA) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. ENDRA Life Sciences Inc. filed a 10-Q report for the period ending
• ENDRA Life Sciences Files S-1/A Amendment — S-1/A · May 10, 2024 Risk:
  ENDRA Life Sciences Inc. (NDRA) filed a Amended IPO Registration (S-1/A) with the SEC on May 10, 2024. ENDRA Life Sciences Inc. filed an S-1/A amendment on May
• ENDRA Life Sciences Faces Delisting Concerns — 8-K · May 3, 2024 Risk: high
  ENDRA Life Sciences Inc. filed an 8-K on May 3, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is incorporate
• ENDRA Life Sciences Inc. Files S-1 Registration Statement — S-1 · Apr 19, 2024 Risk: low
  ENDRA Life Sciences Inc. (NDRA) filed a IPO Registration (S-1) with the SEC on April 19, 2024. ENDRA Life Sciences Inc. filed an S-1 registration statement with
• ENDRA Life Sciences Inc. Files 2023 Annual Report (10-K) — 10-K · Mar 28, 2024 Risk: medium
  ENDRA Life Sciences Inc. (NDRA) filed a Annual Report (10-K) with the SEC on March 28, 2024. ENDRA Life Sciences Inc. reported its 2023 fiscal year-end results

Risk Profile

Risk Assessment: Of NDRA's 38 recent filings, 7 were flagged as high-risk, 16 as medium-risk, and 15 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Endra Life Sciences INC.'s most recent 10-Q filing (Nov 14, 2025):

• Revenue: N/A
• Net Income: $ -1,595,959
• EPS: N/A
• Debt-to-Equity: 10.46
• Cash Position: $ 794,036
• Operating Margin: N/A
• Total Assets: $ 1,964,108
• Total Debt: $ 992,421

Key Executives

• Richard Jacroux
• Alexander Tokman
• Mark R. Busch, Esq.
• Coleman Wombwell, Esq.
• Robert Charron, Esq.
• Michael Thornton
• Dr. Jonathan M. Rothberg
• Mr. David M. Schlotterbeck
• Mr. Michael L. Blue
• Francois Michelon

Industry Context

ENDRA Life Sciences operates in the medical imaging technology sector, focusing on ultrasound solutions. The industry is characterized by rapid technological advancements, significant R&D investment requirements, and a complex regulatory approval process. Companies in this space compete on innovation, clinical efficacy, and market adoption, often facing long sales cycles and the need for substantial capital to scale.

Top Tags

SEC Filing (5) · 8-K (4) · disclosure (4) · 10-Q (4) · financials (4) · filing (4) · ENDRA Life Sciences (4) · Medical Devices (3) · 8-k (3) · financial-reporting (3)

Key Numbers

• Cash at September 30, 2025: $794,036 — Decreased from $3,229,480 at December 31, 2024, a 75.4% decline.
• Net Loss (Q3 2025): $1,595,959 — Improved from $2,354,090 in Q3 2024, a 32.2% reduction.
• Net Loss (YTD Q3 2025): $3,858,201 — Improved from $7,358,943 in YTD Q3 2024, a 47.6% reduction.
• Total Stockholders' Equity: $171,380 — Decreased from $2,560,366 at December 31, 2024, a 93.3% decline.
• Research and Development Expenses (YTD Q3 2025): $1,341,859 — Decreased from $2,552,336 in YTD Q3 2024, a 47.4% reduction.
• Common Stock Shares Outstanding: 1,166,441 — As of November 14, 2025.
• Proposed authorized common stock: 1,000,000,000 shares — Increased from 20,000,000 shares, a 4,900% increase
• Current authorized common stock: 20,000,000 shares — Proposed to be increased to 1,000,000,000 shares
• Date of Annual Meeting: December 9, 2025 — Stockholders will vote on proposals
• Record Date: October 16, 2025 — Determines stockholders entitled to vote
• Outstanding common stock: 1,166,441 shares — As of the record date, entitled to 1,166,441 votes
• Outstanding Series A Preferred Stock: 17.488 shares — As of the record date, entitled to approximately 1 vote
• Votes per Series A Preferred Stock share: 11 votes — Approximately, as of the record date
• Number of director nominees: 4 — To be elected for one-year terms
• Net Loss (Q2 2025): $1.23M — Decreased from $2.23M in Q2 2024, showing improved financial performance.

Frequently Asked Questions